Foley Attorneys Recognized in Chambers Global 2021 Guide
February 18, 2021
Chambers 2021 Guide
Foley & Lardner LLP announced today that five of its attorneys have been recognized in the Chambers Global 2021 guide. In addition, the firm was recognized for three practice areas in the U.S. and Mexico.
- Kathryn Trkla was recognized for Capital Markets: Derivatives and Capital Markets: Derivatives: Mainly Regulatory in the U.S.
- John Eliason and Thomas Hoffman were recognized for Projects: Renewables & Alternative Energy in the U.S.
- Fernando Camarena Cardona and Roberto Arena Reyes Retana were recognized for Tax: Non-Contentious in Mexico.
The firm was recognized for its Projects: Power & Renewables: Transactional and its Projects: Renewables & Alternative Energy practices in the U.S. and its Tax: Non-Contentious practice in Mexico.
To compile its annual lists, Chambers and Partners conducted thousands of interviews with attorneys and their clients in a wide range of industries. Interview participants were asked to recommend attorneys and firms they use most often for top-tier legal work.
People
Related News
August 13, 2025
In the News
Leigh Riley on Elevating Partner Development with Foley's PEAK Program – 'We can't stop learning'
Foley & Lardner LLP partner Leigh Riley appeared on the Big Law Life podcast to share how Foley is redefining professional development to meet the needs of the firm's partners and the demands of modern legal practice.
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."